Menu
Not yet recruiting NCT07235995

Paracetamol and Mannitol Injection and Postoperative Delirium

Phase IV Interventional Postoperative Delirium Elderly Non Cardiac Surgery

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Acetaminophen group, Sufentanil group.
Who it may be relevant to
Registry conditions: Postoperative Delirium, Elderly, Non Cardiac Surgery. Basic parameters: from 60 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Impact of Paracetamol and Mannitol Injection Analgesia on Postoperative Delirium in Elderly Patients After Non-cardical Surgery: A Randomized Controlled Trial

Overview

The aim of this multi-center RCT is to investigate the effect of intravenous acetaminophen (paracetamol and mannitol injection) on postoperative delirium, comparing with intravenous sufentanil, in elderly noncardiac surgical patients admitted to ICU.

Detailed description

Delirium is a common complication after surgery. It is associated with increased morbidity and mortality, longer intensive care unit (ICU) and hospital stay, prolonged mechanical ventilation, higher risk of institutionalization, and higher healthcare cost. Depending on patient population and screening method, the incidence of delirium in elderly patients admitted to ICU can be as high as 58-76%. The choice of analgesics and the adequacy of pain control are among the modifiable precipitating factors for postoperative delirium (POD). Whether the use of intravenous acetaminophen decreases the occurrence of POD in elderly noncardiac surgical patients admitted to ICU remains inadequately studied.

Objectives: To investigate the effect of intravenous acetaminophen (paracetamol and mannitol injection) on postoperative delirium, comparing with intravenous sufentanil, in elderly noncardiac surgical patients admitted to ICU.

Study design: A randomized controlled trial. Setting: 34 ICUs from different regions across China. Patients: 1092 elderly patients (≥ 60 years), having noncardiac surgery and admitted to ICU after surgery, are eligible.

Intervention: Patients are randomly assigned to intravenous acetaminophen or sufentanil groups. Intravenous acetaminophen is the analgesic of choice for patients in the acetaminophen group. Intravenous sufentanil is the analgesic of choice for patients in the sufentanil group (control).

Outcomes: The primary endpoint is the incidence of delirium within the first 5 days after surgery. Delirium is assessed using the confusion assessment method for the intensive care unit (CAM-ICU). The secondary endpoints include the level of pain assessed using the Numeric Rating Scale (NRS) on postoperative day 1 to 5 and day 30, 30-day mortality, length of ICU and hospital stay, quality of life assessed on postoperative day 30, cognitive function assessed on postoperative day 30, and biomarkers and neurofunctional testing for delirium.

Predicted duration of the study: 24 months.

Interventions

  • Drug Acetaminophen group
    The pain in this group is controlled using acetaminophen (Paracetamol and Maninitol Injection, Yichang Renfu Medicine Co., Ltd., China), 500 mg, intravenous bolus, every 6 hours for the first 48 hours postoperatively. The severity of pain is assessed using NRS every 15 minutes during the first hour following ICU admission and then once every 12 hours needed.
  • Drug Sufentanil group
    he pain in this group is controlled using sufentanil (Yichang Renfu Medicine Co., Ltd., China) intravenous infusion with a rate of 0.05 μg/kg/h. The severity of pain is assessed using NRS every 15 minutes during the first hour following ICU admission and then once every 12 hours needed.

Primary outcome measures

  • Rate of delirium [Time frame: postoperative 1- 5 days]
Secondary outcome measures (7)
  • All-cause mortality [Time frame: 30-day after surgery]
  • Severity of pain [Time frame: postoperative days 1-5]
  • Length of ICU stay [Time frame: immediately after surgery]
  • Length of hospital stay [Time frame: immediately after surgery]
  • Quality of life of 30-day survivors [Time frame: day 30 after surgery]
  • Cognitive function of 30-day survivors [Time frame: day 30 after surgery]
  • Incidence of non-delirium-related complications [Time frame: 30 days after surgery]

Eligibility criteria

Inclusion criteria

  • Age ≥ 60 years;
  • Admitted to ICU after a noncardiac surgical procedure
  • Moderate to severe acute pain, with a postoperative pain score ≥ 5 based on the 11-point Numerical Pain Rating Scale (NPRS)
  • Signed informed consent form

Exclusion criteria

  • Preoperative medical history: schizophrenia, epilepsy, Parkinson's disease, or severe myasthenia gravis
  • History of psychiatric disease or significant neurocognitive disorder such as dementia or retardation, making POD assessment impossible
  • Language or communication barrier making POD assessment impossible
  • Intracranial surgery
  • Severe hepatic dysfunction prohibiting the use of acetaminophen per the standard of care
  • Participation in a competing study within 30d
  • Patients experienced intraoperative or postoperative complications, and the investigator determined the subject was unsuitable to continue participation in the study
  • Intolerant to paracetamol or opioid drugs

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Double blind
Primary purpose
Prevention

Study locations

China · 1 center
  • Xiangya hospital — Changsha

Identifiers

NCT: NCT07235995 · 202510115 · 202510115

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗